Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
γδ T Cell Immunotherapy for Lung Cancer
NCT03183232Phase 2Completed
- Sponsor
- Fuda Cancer Hospital
- Start
- Jun 2017
- Primary completion
- Jun 2018
- Modality
- Prophylactic Vaccines, Cell Therapies, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic gamma-delta T cells in lung cancer, sponsored by Fuda Cancer Hospital. Started Jun 2017; status: completed.
02
Drugs
allogeneic gamma-delta T cells
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT03183232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03183232.